# OnCo record tigilanol-tiglate (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tigilanol-tiglate/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tigilanol-tiglate" ;
  schema:name "Tigilanol tiglate"@en ;
  schema:alternateName "Stelfonta"@en, "EBC-46"@en, "tigilanol tiglate injection"@en, "Stelfonta" ;
  schema:description "Tigilanol tiglate (Stelfonta) is an injection into the tumour, approved by the US Food and Drug Administration in 2020 to treat mast cell tumours in dogs. In people it is still experimental and is being tested in sarcoma and head and neck cancer."@en ;
  schema:url <https://onco.cc/drugs/tigilanol-tiglate/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know>, <https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/9988>, <https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-intratumoral-injection-treat-non-metastatic-mast-cell-tumors-dogs>, <https://clinicaltrials.gov/study/NCT05755113>, <https://clinicaltrials.gov/study/NCT05608876> ;
  onco:status "phase-2" ;
  onco:tag "veterinary", "comparative-oncology" ;
  onco:modality "small molecule (intratumoural injection)" ;
  onco:related <https://onco.cc/ideas/idea-bio1-comparative-oncology-dogs/>, <https://onco.cc/journals/veterinary-and-comparative-oncology/> ;
  onco:targets <https://onco.cc/targets/pkc/> ;
  onco:companies <https://onco.cc/companies/qbiotics/> ;
  onco:trials <https://onco.cc/trials/nct05755113/>, <https://onco.cc/trials/nct05608876/> .